泛PPAR激动剂拉尼兰诺改善2型糖尿病合并MASLD患者的胰岛素抵抗和肝脂肪变
这项单中心II期研究将38例2型糖尿病合并MASLD患者按1:1随机分配接受拉尼兰诺800 mg或安慰剂治疗24周。拉尼兰诺显著降低肝内甘油三酯含量(FAS -44% vs -12%),并改善肝脏、肌肉和脂肪组织胰岛素抵抗,安全有效。
要点
- 拉尼兰诺800 mg治疗24周使肝内甘油三酯较安慰剂显著降低(FAS -44% vs -12%)。
- 拉尼兰诺组更多患者达到≥30%肝内甘油三酯下降(FAS 65% vs 22%)和脂肪变消退(FAS 25% vs 0%)。
- 拉尼兰诺显著改善肝脏和外周胰岛素抵抗,脂联素增加2.4倍,不良事件轻微。
核心结论
- 拉尼兰诺显著改善肝脏、肌肉和脂肪组织胰岛素抵抗。
- 拉尼兰诺治疗在减少肝脂肪变和代谢功能障碍相关心血管代谢危险因素方面安全有效。
研究设计与样本
- 单中心II期研究,38例2型糖尿病合并MASLD患者按1:1随机分配接受拉尼兰诺800 mg或安慰剂治疗24周。
- 主要终点为肝内甘油三酯含量变化(1H-MRS)。
- 主要预设次要终点为肝脏、肌肉和脂肪组织胰岛素敏感性变化,采用高胰岛素-正葡萄糖钳夹技术测量葡萄糖周转。
主要发现
- 拉尼兰诺较安慰剂显著降低肝内甘油三酯(FAS -44% vs -12%,最小二乘均值差-31%,95%CI -51至-12%;完成者-50% vs -16%;均p<0.01)。
- 拉尼兰诺组较安慰剂组更多患者达到≥30%肝内甘油三酯下降(FAS 65% vs 22%;完成者79% vs 29%;均p<0.01)和脂肪变消退(FAS 25% vs 0%;p<0.05)。
- 拉尼兰诺显著改善肝脏和外周胰岛素抵抗(空腹内源性葡萄糖生成、肝脏胰岛素抵抗、胰岛素刺激的肌肉葡萄糖处置或Rd)。
- 拉尼兰诺改善空腹血糖、胰岛素、HOMA-IR、HbA1c、HDL-C,脂联素增加2.4倍(均p<0.001)。
- 拉尼兰诺导致体重轻度增加(+2.7%);不良事件轻微(胃肠道副作用、血红蛋白下降),导致研究中止的药物相关治疗中出现的不良事件在组间均衡。
关键数值与推荐
- FAS中拉尼兰诺组65% vs 安慰剂组22%达到≥30%肝内甘油三酯下降(p<0.01)。
- FAS中拉尼兰诺组25% vs 安慰剂组0%实现脂肪变消退(p<0.05)。
- 拉尼兰诺组脂联素增加2.4倍(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lanifibranor is a pan-PPAR agonist that improves glucose/lipid metabolism and reverses steatohepatitis and fibrosis in adults with metabolic dysfunction-associated steatohepatitis (MASH). We tested its effect on insulin resistance (IR) at the level of different target tissues in relation to changes in intrahepatic triglyceride (IHTG) content. METHODS: In this single-center phase II study, 38 patients with type 2 diabetes and MASLD were randomized 1:1 to receive lanifibranor 800 mg or placebo for 24 weeks. The primary endpoint was the change in IHTG (1H-MRS). The main prespecified secondary endpoint was the change in hepatic, muscle and adipose tissue insulin sensitivity using the gold-standard euglycemic hyperinsulinemic clamp technique to measure glucose turnover. Other secondary endpoints included changes in cardiometabolic parameters (i.e., HbA1c, lipid profile, adiponectin). RESULTS: Lanifibranor significantly lowered IHTG compared to placebo (full analysis set [FAS] -44% vs. -12%, respectively; least squares mean difference -31%, 95% CI -51 to -12%; in completers -50% vs. -16%; both p <0.01). More patients in the lanifibranor group (vs. the placebo group) achieved a ≥30% IHTG reduction (FAS 65% vs. 22%; completers 79% vs. 29%; both p <0.01) and steatosis resolution (FAS 25% vs. 0%; p <0.05). Lanifibranor significantly improved hepatic and peripheral IR (i.e. fasting endogenous [primarily hepatic] glucose production, hepatic IR, and insulin-stimulated muscle glucose disposal or Rd). Secondary metabolic endpoints also improved (fasting glucose, insulin, HOMA-IR, HbA1c, HDL-C), and adiponectin increased 2.4-fold (all p <0.001). Lanifibranor caused modest weight gain (+2.7%). Adverse events were mild (gastrointestinal side effects, hemoglobin decrease) and drug-related treatment-emergent adverse events leading to study discontinuation were balanced between groups. CONCLUSIONS: Lanifibranor significantly improves hepatic, muscle and adipose tissue IR. Lanifibranor treatment was safe and effective in reducing hepatic steatosis and cardiometabolic risk factors associated with metabolic dysfunction. IMPACT AND IMPLICATIONS: No prior studies have evaluated the effect of lanifibranor on insulin sensitivity at the level of muscle, liver and adipose tissue and its relationship to changes in intrahepatic triglyceride (IHTG) content in insulin-resistant individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes. We observed a significant decrease in IHTG after 24 weeks of treatment (by ∼50%, p <0.001 vs. placebo) that was associated with a major improvement in hepatic and peripheral (Rd) insulin sensitivity, restoration of adipose tissue function and improvement in cardiometabolic risk factors. This study has important clinical implications because it offers proof-of-concept that targeting the key underlying metabolic defects in MASLD (i.e. insulin resistance, lipotoxicity and hyperglycemia) can restore cardiometabolic health. It offers a compelling rationale for lanifibranor treatment in individuals with MASLD, either alone or in combination with weight loss and other treatment strategies. GOV IDENTIFIER: NCT03459079.
引用
- Barb D, Kalavalapalli S, Godinez Leiva E, et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. J Hepatol. 2025. PMID: 39824443. doi:10.1016/j.jhep.2024.12.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。